ViewRay Incorporated
RELATED CONTENT
February 27, 2017 — ViewRay Inc. announced that the company received 510(k) clearance from the U.S. Food and Drug ...
February 27, 2017 
In 2016, the America Cancer Society expected 1,685,210 new cancer diagnoses in the United States alone. And according to the National Cancer Institute, approximately half of all patients diagnosed with cancer will undergo radiation therapy as part of their treatment plan. Given the large number of patients turning to radiation oncology, it is no wonder there is an immense focus on continually advancing this treatment technique. Millions of lives depend upon it.
February 01, 2017 
August 9, 2016 — ViewRay Inc. announced highlights from the recent 2016 Annual Meeting of the American Association of ...
August 09, 2016 
As radiation therapy continues to evolve, new techniques and technologies are largely focused on maximizing the dose to the tumor site while protecting surrounding tissue as much as possible. Image guidance is a critical component of treatment planning for tumor delineation and gauging treatment response, and cone beam computed tomography (CBCT) has traditionally been the modality of choice.
June 01, 2016 
Computed tomography (CT) has long been the gold standard for image acquisition during radiation therapy treatment planning, as the ability to visualize tumor position and volume in 3-D is integral for prescribed dose calculations.
February 03, 2016 
ViewRay Inc. announced in late July its successful completion of a reverse merger with ViewRay Technologies Inc. The combined entity will focus solely on the business of ViewRay, the makers of MRIdian, the world's first and only commercial magnetic resonance image (MRI)-guided radiation therapy system that images and treats cancer patients simultaneously. ViewRay will trade on the OTC Markets under the symbol "VRAY."
August 17, 2015 ViewRay's MRIdian System, the world's first and only magnetic resonance imaging (MRI)-guided radiation therapy system, was featured during the 2015 annual meeting of the American Association of Physicists in Medicine (AAPM). This year's meeting was held July 12-16 in Anaheim, California.
July 22, 2015 
Image-guided radiation therapy (IGRT) affords greater accuracy of dose distribution during cancer treatment, allowing the radiation oncologist to see how a tumor is responding over the course of treatment. This has traditionally been accomplished with computed tomography (CT) or X-ray scans, which requires extra radiation exposure for the patient, with relatively poor contrast in soft tissue due to uniform electron density. Since treatment is only as good as the images provided, efforts are under way to find a better modality — and magnetic resonance imaging (MRI) may hold the answer.
July 06, 2015 
ViewRay announced that the company has secured up to $50 million in debt financing from CRG (formerly Capital Royalty L.P.), a premier healthcare investment firm.
June 30, 2015 
ViewRay announced that it has entered into an exclusive distributor agreement with Itochu Corporation to sell its MRI-guided radiation therapy system for the treatment of cancer in Japan.
January 26, 2015